Filing Details

Accession Number:
0000899243-19-025695
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-17 16:55:46
Reporting Period:
2019-10-16
Accepted Time:
2019-10-17 16:55:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1706431 Vir Biotechnology Inc. VIR Biological Products, (No Disgnostic Substances) (2836) 812730369
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1731509 Ltd (Uk) Advisers Investment Sb 69 Grosvenor Street
London X0 W1K 3JW
No No Yes No
1755143 L.p. M1) (Aiv Fund Vision Softbank 251 Little Falls Drive
Wilmington DE 19808
No No Yes No
1782338 Ltd (Cayman) Endurance Svf C/O Walkers Corp Ltd Cayman Corp Centre
27 Hospital Road
Georgetown, Grand Cayman E9 KY1-9008
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Acquisiton 2019-10-16 21,666,666 $0.00 21,666,666 No 4 C Indirect See footnote
Common Stock, Par Value $0.0001 Per Share Acquisiton 2019-10-16 950,000 $20.00 22,616,666 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Convertible Preferred Stock Disposition 2019-10-16 15,555,555 $0.00 15,555,555 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2019-10-16 6,111,111 $0.00 6,111,111 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series A-1 Convertible Preferred Stock and the Series B Convertible Preferred Stock each converted into Vir Biotechnology, Inc. common stock on a one-to-one basis and had no expiration date.
  2. Represents securities held directly by SVF Endurance (Cayman) Limited. SVF Endurance (Cayman) Limited is a wholly-owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
  3. (continued from footnote 2) SBIA UK is wholly owned by SoftBank Group Corp. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission that any reporting person is the beneficial owner of such shares for purposes of the Securities Exchange Act of 1934 or for any other purpose.